Congratulations to first author, Dr. Brent Scott, and our collaborators at the University of Kentucky, Drs. Caterina Squari and Ken Campbell. We show that although danicamtiv was originally described as a myosin activator, its molecular mechanism is more complicated, where it likely activates the sarcomere through the thin filament. The paper can be found here.